Coherus BioSciences (NASDAQ:CHRS) Cut to “Sell” at StockNews.com

StockNews.com downgraded shares of Coherus BioSciences (NASDAQ:CHRS) from a hold rating to a sell rating in a report released on Friday.

Several other analysts also recently commented on the stock. UBS Group reissued a “neutral” rating and issued a $1.05 target price (down from $1.50) on shares of Coherus BioSciences in a research report on Thursday, April 24th. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Coherus BioSciences in a research report on Tuesday, April 29th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $5.26.

Coherus BioSciences Stock Performance

Shares of CHRS opened at $0.97 on Friday. The company’s 50 day moving average price is $0.95 and its 200 day moving average price is $1.13. Coherus BioSciences has a 52 week low of $0.66 and a 52 week high of $2.43. The company has a market capitalization of $111.95 million, a PE ratio of -12.07 and a beta of 1.01.

Institutional Trading of Coherus BioSciences

Several large investors have recently modified their holdings of CHRS. Steph & Co. bought a new stake in shares of Coherus BioSciences during the 4th quarter worth $34,000. Tyche Wealth Partners LLC boosted its holdings in shares of Coherus BioSciences by 23.6% during the 4th quarter. Tyche Wealth Partners LLC now owns 266,766 shares of the biotechnology company’s stock worth $368,000 after buying an additional 50,864 shares during the period. Savant Capital LLC bought a new stake in shares of Coherus BioSciences during the 4th quarter worth $130,000. Ieq Capital LLC bought a new stake in shares of Coherus BioSciences during the 4th quarter worth $68,000. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Coherus BioSciences by 26.6% during the 4th quarter. Bank of New York Mellon Corp now owns 391,002 shares of the biotechnology company’s stock worth $540,000 after buying an additional 82,222 shares during the period. 72.82% of the stock is owned by institutional investors.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.